Videos

  
The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed what can currently be surmised about siponimod’s effect in treating patients with SPMS.
Key opinion leaders agree there is no consensus on choosing initial therapy for treatment of multiple sclerosis.
In episode 6, Clyde E. Markowitz, MD, gives a review of data from the ACTRIMS 2020 meeting in light of 6-year follow-up data with ocrelizumab therapy.
In episode 5, Patricia Coyle, MD details the six-year data from the phase 3 OPERA I/II studies on the use of ocrelizumab and the impact on confirmed disability progression in patients with multiple sclerosis.
The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.
An overview of neurofibromatosis type 1 and how to diagnose the rare disorder. 
The director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine detailed the comorbidities related to narcolepsy.  
Panelists discuss the importance and value of early identification and treatment of multiple sclerosis.
Recommendations for utilizing ocrelizumab for the treatment of relapsing multiple sclerosis (MS) and primary progressive MS based on the most current clinical trial data.
SAP Partner Banner